pioneer 6 oral semaglutide cardiovascular outcomes trial results (SUSTAIN and PIONEER) reduces events in type 2 diabetes across varying cardiovascular risk SOUL: Oral Semaglutide Bests Usual

1 Type 2 diabetes can be challenging enough to manage without the added risk of chronic kidney disease, and I have seen in my own practice that patients with type 2 diabetes and chronic kidney disease need extra support from medications that may have a profound clinical impact by lowering the risk of major kidney and cardiovascular outcomes, said Richard E

But identifying who might be at higher risk allows for more informed decision-making and earlier recognition if symptoms develop

Empower itself has faced regulatory scrutiny, with the FDA issuing warning letters as recently as April citing problems with sterile drug production and contamination controls, according to a Houston Chronicle investigation

Feels easier to follow as a daily routine for many